Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.

Revenue projections:

Revenue projections for SUVENPHAR
Revenue projections for SUVENPHAR

Revenues for SUVENPHAR are expected to drop compared to the previous year, which could be a cause for concern for investors. A decline in earnings may negatively impact the company's profitability, leading cautious investors to reconsider their positions, as it often signals challenges in overall financial health.

Financial Ratios:

currentRatio 0.000000
forwardPE 56.269436
debtToEquity 1.945000
earningsGrowth 0.755000
revenueGrowth 0.397000
grossMargins 0.627760
operatingMargins 0.316950
trailingEps 10.900000
forwardEps 0.000000

SUVENPHAR's high forward PE suggests a risk of overvaluation, which could curtail further price gains and lead to a correction. Investors should carefully weigh this metric alongside other fundamental indicators to gauge the stock's overall financial health.
SUVENPHAR's positive growth in earnings and revenue suggests the company is on track to expand its business. These indicators highlight a healthy financial performance, with SUVENPHAR expected to increase its market presence and profitability.
Suven Pharmaceuticals Limited's positive gross and operating margins indicate a profitable and efficient business model. These metrics highlight the company's ability to generate income while controlling operational costs, reflecting strong financial performance.

Price projections:

Price projections for SUVENPHAR
Price projections for SUVENPHAR

The price of Suven Pharmaceuticals Limited currently aligns with projections, offering no clear risks or opportunities. This situation suggests stability in the stock's performance, leading investors to await further developments before making strategic decisions.

Recommendation changes over time:

Recommendations trend for SUVENPHAR
Recommendations trend for SUVENPHAR


Analysts' buy bias for Suven Pharmaceuticals Limited signals that the stock is considered a favorable investment. This outlook might prompt investors to allocate funds to Suven Pharmaceuticals Limited, seeing it as a solid and profitable choice to park their money and potentially benefit from the company's long-term growth.